Sign in

‘No difference of opinion with AYUSH Ministry’: Patanjali issues statement

Patanjali claims that the AYUSH ministry has categorically agreed that “Patanjali Research Foundation has appropriately worked on Covid-19 management”.

Updated on: Jul 1, 2020, 14:12:52 IST
Hindustan Times, New Delhi | By
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

Patanjali Ayurved Ltd., on Wednesday, issued a statement saying that all documents related to the Covid-19 clinical trial have been shared with the AYUSH Ministry and that there exists “no difference of opinions between the ministry and Patanjali.

File photo: Yoga guru Ramdev addresses the media during the launch of 'Coronil' and 'Swasari' - ayurvedic medicines claimed by Patanjali to cure coronavirus disease in Haridwar. (PTI)
File photo: Yoga guru Ramdev addresses the media during the launch of 'Coronil' and 'Swasari' - ayurvedic medicines claimed by Patanjali to cure coronavirus disease in Haridwar. (PTI)

In the statement, Patanjali said that Covid-19 patients group that received its medicines, showed 67% recovery in 3 days and 100% recovery in 7 days of treatment. “That is, all 45 patients became Covid-19 negative,” the statement read.

Patanjali claims that the ministry has categorically agreed that “Patanjali Research Foundation has appropriately worked on Covid-19 management”.

As per the statement, Patanjali says it is allowed by the Ministry to “manufacture and distribute its Divya Coronil Tablets, Divya Swasarvati and Divya AnuTaila across India”.

The company said that it has procured the licence approval for Divya Coronil tablet and Divya Swasarivati on their “traditional reported usage”.

“Ayurvedic drug licences and control clinical trials are two different streams,” the statement read.

This comes a day after Acharya Balkrishna, the chief executive officer of Patanjali clarified that the company never claimed that its newly-tested medicines would treat Covid-19.

“We cited Coronil as ayurvedic medicine for immunity boosting, fever, cough and allergic problems,” Balkrishna said, adding, “Only results of clinical trial based curing of positive patients were claimed by us”.

Last week, Patanjali Ayurved launched a drug called “Coronil”, claiming that it had cured within a week all Covid-19 patients who took part in a trial conducted in Jaipur.

The claim triggered a row with the Union AYUSH ministry directing the firm not to sell the drug.

Uttarakhand’s Ayurveda department said the firm had only applied for a licence to manufacture an immunity booster and not a cure for coronavirus.

In reply to a notice by the Uttarakhand government, Patanjali clarified not promoting any “kit” to treat Covid-19 and only sharing the findings of the “successful trial” of a medicine on patients.

  • HT News Desk
    ABOUT THE AUTHOR
    HT News Desk

    Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.Read More